肿瘤抑素19肽对乳腺癌移植瘤生长的实验研究

Experimental Study of Tumstatin 19 Peptide on Growth of Implanted Breast Cancer

目的:探讨肿瘤抑素19肽对乳腺癌MDA-MB-231细胞增殖能力的影响,并观察其在乳腺癌动物模型中对移植瘤生长的影响。方法:应用甲基四噻唑蓝(MTT)法检测19肽对乳腺癌MDA-MR-231细胞的影响,将乳腺癌裸鼠原位移植瘤模型分为4组,隔日腹腔给药方法分别给予19肽、环磷酰胺、19肽+环磷酰胺、溶剂治疗,记录各组移植瘤的治疗变化,并进行统计学分析。结果:MTT显示乳腺癌MDA-MB-231细胞的生长随19肽浓度的增加存活率降低,19肽治疗组和联合用药组毒副作用较环磷酰胺组小,体重差异有统计学意义(P=0.010,P=0.032);治疗组与对照组瘤重差异均有统计学意义(P均<0.05)。结论:19肽可抑制体外培养的乳腺癌MDA-MB-231细胞的生长;19肽体内毒副反应较小,其与环磷酰胺联合后,对移植瘤的抑制能力得到增强,并减轻后者的毒副反应。

Objective： To explore and observe the effects of Tumstatin 19 peptide on the proliferation ability of MDA-MB-231 breast cancer cells and on the growth of implanted tumor in the animal models of breast cancer. Methods： Thiazolyl blue tetrazolium bromide （ MTT ） assay was used to detect the inhibitory action of Tumstatin 19 peptide on the growth of MDA-MB-231 breast cancer ceils. The orthotopically implanted breast cancer models in nude mice were divided into four groups. The 19 peptide, cyclophosphamide, cyclophosphamide ＋ 19 peptide, and solvent treatment were intraperitoneally given every other day in to the nude mice of each group. The changes after treatment for the implanted tumor in each group were recorded, and the results were statistically analyzed. Results： The results of the MTT assay showed that the viability of the MDA-MB-231 breast cancer cells decreased with increasing concentrations of the 19 peptide. The side effects were less in the Tumstatin 19 peptide treatment group and combination groups than in the cyclophosphamide group. There were statistically significant differences in tumor weight among the treatment groups. The P values were 0.010 and 0.032, respectively. There was statistical significance in the difference of the tumor weights between the treatment and the control group. The mean value of P was less than 0.05. Conclusion： In vitro, Tumstatin 19 peptide can inhibit the growth of MDA-MB-231 breast cancer cells. In vivo, the effect of Tumstatinl9 peptide is gentle with less toxicity. When the 19 peptides combine with cyclophosphamide, the inhibition of tumor growth is enhanced, and the toxicity of cyclophosphamide is significantly reduced.